Clinical trial · Observational
Clinical Trial Multi-analyte Blood Test
Prospective Clinical Trial to Detect Liver Cancer Through Quantification of cfDNA Methylation in Blood Samples: A LAM Insight Trial Study
NCT03694600CI-TRIAL-00117555CLiMBactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a clinical trial designed to evaluate the performance of a multi-analyte blood test alone to ultrasound alone for the detection of HCC within a population that is at high risk for HCC due to liver cirrhosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cirrhosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Multi-analyte blood Test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- men or women between 21-84
- description
- Multi-analyte blood test alone versus ultrasound in subjects diagnosed with liver cirrhosis
- interventionNames
- Diagnostic Test: Multi-analyte blood Test
Primary outcomes (1)
- measure
- Independent performance measure of sensitivity and specificity of a multi-analyte blood test vs ultrasound
- timeFrame
- 1 month
- description
- The primary objective is to compare the performance (sensitivity and specificity) of the multi-analyte blood test alone to ultrasound alone for the detection of liver cancers within a high-risk population.
Secondary outcomes (1)
- measure
- Independent performance measure of sensitivity and specificity of a multi-analyte blood test vs ultrasound for the detection of liver cancer lesions that are ≤ 4 cm in diameter.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 84 Years
Show eligibility criteria text
Inclusion Criteria: * Subject is age 21 to 84 (inclusive) * Subject is able to read, comprehend and sign the Informed Consent Document * Subject is willing and able to undergo liver cancer surveillance by ultrasound and the multi-analyte blood Test * Subject is able and willing to undergo diagnostic imaging by multiphasic MRI with contrast according to the Study Protocol * Subject has been diagnosed with liver cirrhosis by one or more of the following methods: 1. Clinical diagnosis by blood analytes (APRI ≥ 1.5 or Bonacini cirrhosis discriminant score ≥ 8 or Lok index \> 0.5) 2. Ultrasound and Elastography \> 12.5 kPa (Vibration-controlled transient elastography, Point shear wave elastography, Two-dimensional shear wave ultrasound and transient elastography or Magnetic Resonance Elastography) 3. Diagnostic imaging by CT or MRI (liver cirrhosis indicated on radiology report) 4. Liver biopsy (liver cirrhosis indicated on pathology report) Exclusion Criteria: * The study investigator deems the subject's participation to be unsafe due to an underlying medical condition * Subject has previously been diagnosed with a primary liver cancer or a non-liver cancer that has metastasized * Subject has previously submitted a blood sample to Helio Health (HELIO) through a separate clinical protocol * Subject is unable or unwilling to submit blood samples for testing, undergo ultrasound or undergo diagnostic imaging by multiphasic MRI with contrast as required for the Study Protocol * Subject has any internal metallic device or fragment, including but not limited to: A pacemaker, artificial joint or valve, surgical clips, pins, plates, screws, wire mesh or shrapnel * It is unsafe for the subject to receive an MRI contrast dye due to pregnancy or severe kidney disease * Subject would not routinely be recommended for HCC surveillance * Subject received an abdominal ultrasound or diagnostic imaging by MRI or CT to image the liver within the past 5 months
References
Publications (1)
- DERIVEDTaggart DJ, Mahajan S, Gallant MA, Pinkoviezky I, Xu J, Sorg AJ, Roberts CC, Slinkov D, Gorospe EC, Mubarak A, Bhandari BR, Freilich B, Gunn N, Yang JD, Smith JH, Younes ZH, Cabrera R, Aguilar H, Samant H, Li W, Van Etten RA, Nguyen MH. A multi-analyte cfDNA-based blood test for early detection of hepatocellular carcinoma. J Hepatol. 2026 May 6:S0168-8278(26)00215-1. doi: 10.1016/j.jhep.2026.04.012. Online ahead of print. PMID 42102976